Promentis Pharmaceuticals, Inc. Awarded $1,800,000 Phase II SBIR Grant to Develop More Effective Drugs for the Treatment of Schizophrenia
September 25, 2012
Promentis Pharmaceuticals, Inc. announced today that it has received a Phase II Small Business Innovation Research (SBIR) award from the National Institute of Mental Health (NlMH) of the National Institutes of Health. The three-year award, totaling $1.8 million, is the continuation of a Phase I SBIR grant received previously by Promentis to develop novel compounds to treat schizophrenia.
About Promentis Pharmaceuticals, Inc:
Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system (CNS) disorders. Support for Promentis’ drug discovery and development programs, in part, has been provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation. Additional information can be found at www.promentispharma.com.
Media Inquiries:
Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 375-2694
amielach@tiberend.com
SOURCE Promentis Pharmaceuticals, Inc.
RELATED LINKS